May Non-antipsychotic drugs improve cognition of schizophrenia patients?

Pharmacopsychiatry

Volumn 48, Issue 2, 2015, Pages 41-50

  Buoli, M ^a   Altamura, A C ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

cognition; psychopharmacology; schizophrenia

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ARMODAFINIL; ATOMOXETINE; BUSPIRONE; CELECOXIB; CHOLINERGIC RECEPTOR STIMULATING AGENT; CITALOPRAM; CYPROHEPTADINE; DONEPEZIL; DULOXETINE; FLUVOXAMINE; GALANTAMINE; LAMOTRIGINE; MEMANTINE; MIANSERIN; MIFEPRISTONE; MIRTAZAPINE; MODAFINIL; OMEGA 3 FATTY ACID; PSYCHOTROPIC AGENT; REBOXETINE; RIVASTIGMINE; ROSIGLITAZONE; SEROTONIN 1A AGONIST; SEROTONIN 1A PARTIAL AGONIST; TANDOSPIRONE; TOPIRAMATE; UNCLASSIFIED DRUG; VALACICLOVIR; NOOTROPIC AGENT;

ATTENTION; COGNITION; COGNITIVE DEFECT; DRUG EFFICACY; EXECUTIVE FUNCTION; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; LEARNING; MEMORY; PRIORITY JOURNAL; PROBLEM SOLVING; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECALL; REVIEW; SCHIZOPHRENIA; TREATMENT OUTCOME; VERBAL MEMORY; VISUAL MEMORY; WORKING MEMORY; COGNITION DISORDERS; COMPLICATION; PSYCHOLOGY;

COGNITION DISORDERS; HUMANS; NOOTROPIC AGENTS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 84924106260     PISSN: 01763679     EISSN: 14390795     Source Type: Journal    
DOI: 10.1055/s-0034-1396801     Document Type: Review

References (107)

1. Milev P., Ho B. C., Arndt S. et al. Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up. Am J Psychiatry: 2005; 162 495 506
2. Buoli M., Caldiroli A., Panza G. et al. Prominent clinical dimension, duration of illness and treatment response in schizophrenia: a naturalistic study. Psychiatry Investig: 2012; 9 354 360
3. Green M. F. Cognitive impairment and functional outcome in schizophrenia and bipolar disorder. J Clin Psychiatry: 2006; 67 e12
4. Albus M., Hubmann W., Mohr F. et al. Neurocognitive functioning in patients with first-episode schizophrenia: results of a prospective 5-year follow-up study. Eur Arch Psychiatry Clin Neurosci: 2006; 2560 442 451
5. Teffer K., Semendeferi K. Human prefrontal cortex: evolution, development, and pathology. Prog Brain Res: 2012; 195 191 218
6. Kasparek T., Rehulova J., Kerkovsky M. et al. Cortico-cerebellar functional connectivity and sequencing of movements in schizophrenia. BMC Psychiatry: 2012; 12 17
7. González-Hernández J. A., Pita-Alcorta C., Padrón A. et al. Basic visual dysfunction allows classification of patients with schizophrenia with exceptional accuracy. Schizophr Res: 2014; 159 226 233
8. Pinkham A. E. Social cognition in schizophrenia. J Clin Psychiatry: 2014; 75 14 19
9. Ekman M., Granstrom O., Omerov S. et al. The societal cost of schizophrenia in Sweden. J Ment Health Policy Econ: 2013; 16 13 25
10. Chou H. H. 1, Twamley E., Swerdlow N. R. Towards medication-enhancement of cognitive interventions in schizophrenia. Handb Exp Pharmacol: 2012; 213 81 111
11. Guo X., Zhai J., Wei Q. et al. Early-stage Schizophrenia Outcome Study (ESOS) Investigators. Neurocognitive effects of first- and second-generation antipsychotic drugs in early-stage schizophrenia: a naturalistic 12-month follow-up study. Neurosci Lett: 2011; 503 141 146
12. Keefe R. S., Bilder R. M., Davis S. M. et al. CATIE Investigators; Neurocognitive Working Group. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry: 2007; 64 633 647
13. Davidson M., Galderisi S., Weiser M. et al. Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). Am J Psychiatry: 2009; 166 675 682
14. Woodward N. D., Purdon S. E., Zald D. H. et al. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol: 2005; 8 457 472
15. Andreasen N. C., Paradiso S., O'Leary D. S. Cognitive dysmetria as an integrative theory of schizophrenia: a dysfunction in cortical-subcortical-cerebellar circuitry? Schizophr Bull: 1998; 24 203 218
16. Galletly C. Recent advances in treating cognitive impairment in schizophrenia. Psychopharmacology (Berl): 2009; 202 259 273
17. Masana M., Castañé A., Santana N. et al. Noradrenergic antidepressants increase cortical dopamine: potential use in augmentation strategies. Neuropharmacology: 2012; 63 675 684
18. Niitsu T., Iyo M., Hashimoto K. Sigma-1 receptor agonists as therapeutic drugs for cognitive impairment in neuropsychiatric diseases. Curr Pharm Des: 2012; 18 875 883
19. Sumiyoshi T., Park S., Jayathilake K. et al. Effect of buspirone, a serotonin1A partial agonist, on cognitive function in schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr Res: 2007; 95 158 168
20. Poyurovsky M., Faragian S., Fuchs C. et al. Effect of the selective norepinephrine reuptake inhibitor reboxetine on cognitive dysfunction in schizophrenia patients: an add-on, double-blind placebo-controlled study. Isr J Psychiatry Rel Science: 2009; 46 213 220
21. Niitsu T., Shirayama Y., Fujisaki M. et al. Fluvoxamine improved cognitive impairments in a patient with schizophrenia. Progr Neuropsychopharmacol Biol Psychiatry: 2010; 34 1345 1346
22. Niitsu T., Fujisaki M., Shiina A. et al. A randomized, double-blind, placebo-controlled trial of fluvoxamine in patients with schizophrenia: a preliminary study. J Clin Psychopharmacol: 2012; 32 593 601
23. Delle Chiaie R., Salviati M., Fiorentini S. et al. Add-on mirtazapine enhances effects on cognition in schizophrenic patients under stabilized treatment with clozapine. Exp Clin Psychopharmacol: 2007; 15 563 568
24. Berk M., Gama C. S., Sundram S. et al. Mirtazapine add-on therapy in the treatment of schizophrenia with atypical antipsychotics: a double-blind, randomised, placebo-controlled clinical trial. Hum Psychopharmacol: 2009; 24 233 238
25. Stenberg J. H., Terevnikov V., Joffe M. et al. Effects of add-on mirtazapine on neurocognition in schizophrenia: a double-blind, randomized, placebo-controlled study. Int J Neuropsychopharmacol: 2010; 13 433 441
26. Stenberg J. H., Terevnikov V., Joffe M. et al. More evidence on proneurocognitive effects of add-on mirtazapine in schizophrenia. Progr Neuropsychopharmacol Biol Psychiatry: 2011; 35 1080 1086
27. Cho S. J., Yook K., Kim B. et al. Mirtazapine augmentation enhances cognitive and reduces negative symptoms in schizophrenia patients treated with risperidone: a randomized controlled trial. Prog Neuropsychopharmacol and Biol Psychiatry: 2011; 35 208 211
28. Poyurovsky M., Koren D., Gonopolsky I. et al. Effect of the 5-HT2 antagonist mianserin on cognitive dysfunction in chronic schizophrenia patients: an add-on, double-blind placebo-controlled study. Eur Neuropsychopharmacol: 2003; 13 123 128
29. Friedman J. I., Ocampo R., Elbaz Z. et al. The effect of citalopram adjunctive treatment added to atipica antipsychotic medications for cognitive performance in patients with schizophrenia. J Clin Psychopharmacol: 2005; 25 237 242
30. Micò U., Bruno A., Pandolfo G. et al. Duloxetine as adjunctive treatment to clozapine in patients with schizophrenia: a randomized, placebo-controlled trial. Int Clin Psychopharmacol: 2011; 26 303 310
31. Lee M. A., Meltzer H. Y. 5-HT(1A) receptor dysfunction in female patients with schizophrenia. Biol Psychiatry: 2001; 50 758 766
32. Piskulić D., Olver J. S., Maruff P. et al. Treatment of cognitive dysfunction in chronic schizophrenia by augmentation of atypical antipsychotics with buspirone, a partial 5-HT(1A) receptor agonist. Hum Psychopharmacol: 2009; 24 437 446
33. Sumiyoshi T., Matsui M., Yamashita I. et al. Effect of adjunctive treatment with serotonin-1A agonist tandospirone on memory functions in schizophrenia. J Clin Psychopharmacol: 2000; 20 386 388
34. Sumiyoshi T., Matsui M., Yamashita I. et al. The effect of tandospirone, a serotonin(1A) agonist, on memory function in schizophrenia. Biol Psychiatry: 2001; 49 861 868
35. Sumiyoshi T., Matsui M., Nohara S. et al. Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment. Am J Psychiatry: 2001; 158 1722 1725
36. Higuchi Y., Sumiyoshi T., Kawasaki Y. et al. Effect of tandospirone on mismatch negativity and cognitive performance in schizophrenia: a case report. J Clin Psychopharmacol: 2010; 30 732 734
37. Citrome L. What role for mood stabilizers? Curr Psychiatry: 2004; 3 23 40
38. Porter R. J., Dhir A., Macdonald R. L. et al. Mechanisms of action of antiseizure drugs. Handb Clin Neurol: 2012; 108 663 681
39. Thomas S. P., Nandhra H. S., Jayaraman A. Systematic review of lamotrigine augmentation of treatment resistant unipolar depression (TRD). J Ment Health: 2010; 19 168 175
40. Goff D. C., Keefe R., Citrome L. Lamotrigine as add-on therapy in schizophrenia: results of 2 placebo-controlled trials. J Clin Psychopharmacol: 2007; 27 582 589
41. Zoccali R. 1, Muscatello M. R., Bruno A. et al. The effect of lamotrigine augmentation of clozapine in a sample of treatment-resistant schizophrenic patients: a double-blind, placebo-controlled study. Schizophr Res: 2007; 93 109 116
42. Vay?soʇlu S., Anil Yaʇc?oʇlu A. E., Yaʇc?oʇlu S. et al. Lamotrigine augmentation in patients with schizophrenia who show partial response to clozapine treatment. Schizophr Res: 2013; 143 207 214
43. Muscatello M. R., Bruno A., Pandolfo G. et al. Topiramate augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study. J Psychopharmacol: 2011; 25 667 674
44. Chaudhry I. B., Soni S. D., Hellewell J. S. et al. Effects of the 5HT antagonist cyproheptadine on neuropsychological function in chronic schizophrenia. Schizophr Res: 2002; 53 17 24
45. Lewis A. S., Picciotto M. R. High-affinity nicotinic acetylcholine receptor expression and trafficking abnormalities in psychiatric illness. Psychopharmacology (Berl): 2013; 229 477 485
46. Lenzi A., Maltinti E., Poggi E. et al. Effects of rivastigmine on cognitive function and quality of life in patients with schizophrenia. Clin Neuropharmacol: 2004; 26 317 321
47. Sharma T., Reed C., Aasen I. et al. Cognitive effects of adjunctive 24-weeks Rivastigmine treatment to antipsychotics in schizophrenia: a randomized, placebo-controlled, double-blind investigation. Schizophr Res: 2006; 85 73 83
48. Chouinard S., Stip E., Poulin J. et al. Rivastigmine treatment as an add-on to antipsychotics in patients with schizophrenia and cognitive deficits. Curr Med Res Opin: 2007; 23 575 583
49. Friedman J. I., Adler D. N., Howanitz E. et al. A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia. Biol Psychiatry: 2002; 51 349 357
50. Howard A. K., Thornton A. E., Altman S. et al. Donepezil for memory dysfunction in schizophrenia. J Psychopharmacol: 2002; 16 267 270
51. Buchanan R. W., Summerfelt A., Tek C. et al. An open-labeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia. Schizophr Res: 2003; 59 29 33
52. Tuʇal O., Yazici K. M., Anil Yaʇcioʇlu A. E. et al. A double-blind, placebo controlled, cross-over trial of adjunctive donepezil for cognitive impairment in schizophrenia. Int J Neuropsychopharmacol: 2004; 7 117 123
53. Freudenreich O., Herz L., Deckersbach T. et al. Added donepezil for stable schizophrenia: a double-blind, placebo-controlled trial. Psychopharmacology (Berl): 2005; 181 358 363
54. Mazza M., Pollice R., Gaspari V. et al. Efficacy of adjunctive donepezil for cognitive impairments in patients with schizophrenia. Clin Ther: 2005; 156 203 209
55. Lee B. J., Lee J. G., Kim Y. H. A 12-week, double-blind, placebo-controlled trial of donepezil as an adjunct to haloperidol for treating cognitive impairments in patients with chronic schizophrenia. J Psychopharmacol: 2007; 21 421 427
56. Fagerlund B., Soholm B., Fink-Jensen A. et al. Effects of donepezil adjunctive treatment to ziprasidone on cognitive deficits in schizophrenia: a double-blind, placebo-controlled study. Clin Neuropharmacol: 2007; 30 3 12
57. Kohler C. G., Martin E. A., Kujawski E. et al. No effect of donepezil on neurocognition and social cognition in young persons with stable schizophrenia. Cogn Neuropsychiatry: 2007; 12 412 421
58. Akhondzadeh S., Gerami M., Noroozian M. et al. A 12-week, double-blind, placebo-controlled trial of donepezil adjunctive treatment to risperidone in chronic and stable schizophrenia. Progr Neuropsychopharmacol Biol Psychiatry: 2008; 32 1810 1815
59. Chung Y. C., Lee C. R., Park T. W. et al. Effect of donepezil added to atypical antipsychotics on cognition in patients with schizophrenia: an open-label trial. World J Biol Psychiatry: 2009; 10 156 162
60. Boggs D. L., Carlson J., Cortes-Briones J. et al. Going up in smoke? A review of nAChRs-based treatment strategies for improving cognition in schizophrenia. Curr Pharm Des: 2013; online
61. Ochoa E. L., Clark E. Galantamine may improve attention and speech in schizophrenia. Hum Psychopharmacol: 2006; 21 127 128
62. Norén U., Björner A., Sonesson O. et al. Galantamine added to antipsychotic treatment in chronic schizophrenia: cognitive improvement? Schizophr Res: 2006; 85 302 304
63. Lee S. W., Lee J. G., Lee B. J. et al. A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia. Int Clin Psychopharmacol: 2007; 22 63 68
64. Dyer M. A., Freudenreich O., Culhane M. A. et al. High-dose galantamine augmentation inferior to placebo on attention, inhibitory control and working memory performance in nonsmokers with schizophrenia. Schizophr Res: 2008; 102 88 95
65. Buchanan R. W., Conley R. R., Dickinson D. et al. Galantamine for the treatment of cognitive impairments in people with schizophrenia. Am J Psychiatry: 2008; 165 82 89
66. Lindenmayer J. P., Kahn A. Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia. Schizophr Res: 2011; 125 267 277
67. Reisberg B., Doody R., Stöffler A. et al. Memantine Study Group Memantine in moderater-to-severe Alzheimer's disease. New Engl J Med: 2003; 348 1333 1341
68. Lieberman J. A., Papadakis K., Csernansky J. et al. MEM-MD-29 Study Group. A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia. Neuropsychopharmacology: 2009; 34 1322 1329
69. Lee J. G. 1, Lee S. W., Lee B. J. et al. Adjunctive memantine therapy for cognitive impairment in chronic schizophrenia: a placebo-controlled pilot study. Psychiatry Investig: 2012; 9 166 173
70. Minzenberg M. J., Carter C. S. Modafinil: a review of neurochemical actions and effects on cognition. Neuropsychopharmacology: 2008; 33 1477 1502
71. Turner D. C., Clark L., Pomarol-Clotet E. et al. Modafinil improves cognition and attentional set shifting in patients with chronic schizophrenia. Neuropsychopharmacology: 2004; 29 1363 1373
72. Hunter M. D., Ganesan V., Wilkinson I. D. et al. Impact of modafinil on prefrontal executive function in schizophrenia. Am J Psychiatry: 2006; 163 2184 2186
73. Kane J. M., D'Souza D. C., Patkar A. A. et al. Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study. J Clin Psychiatry: 2010; 71 1475 1481
74. Friedman J. I., Carpenter D., Lu J. et al. A pilot study of adjunctive atomoxetine treatment to second-generation antipsychotics for cognitive impairment in schizophrenia. J Clin Psychopharmacol: 2008; 28 59 63
75. Rao N. P., Venkatasubramanian G., Gangadhar B. N. Treatment of cognitive deficits in schizophrenia with atomoxetine: a case report. J Clin Psychiatry: 2007; 68 1988 1989
76. Sacco K. A., Creeden C., Reutenauer E. L. et al. Effects of atomoxetine on cognitive function and cigarette smoking in schizophrenia. Schizophr Res: 2009; 107 332 333
77. Altamura A. C., Buoli M., Pozzoli S. Role of immunological factors in the pathophysiology and diagnosis of bipolar disorder: Comparison with schizophrenia. Psychiatry Clin Neurosci: 2014; 68 21 36
78. Müller N., Riedel M., Schwarz M. J. et al. Clinical effects of COX-2 inhibitors on cognition in schizophrenia. Eur Arch Psychiatry Clin Neurosci: 2003; 255 149 151
79. Thomas P., Bhatia T., Gauba D. et al. Exposure to herpes simplex virus, type 1 and reduced cognitive function. J Psychiatr Res: 2013; 47 1680 1685
80. Prasad K. M., Eack S. M., Keshavan M. S. et al. Antiherpes virus-specific treatment and cognition in schizophrenia: a test-of-concept randomized double-blind placebo-controlled trial. Schizophr Bull: 2013; 39 857 866
81. Sumiyoshi T., Matsui M., Itoh H. et al. Essential polyunsaturated fatty acids and social cognition in schizophrenia. Psychiatry Res: 2008; 157 87 93
82. Reddy R., Fleet-Michaliszyn S., Condray R. et al. Reduction in perseverative errors with adjunctive ethyl-eicosapentaenoic acid in patients with schizophrenia: Preliminary study. Prostaglandins Leukot Essent Fatty Acids: 2011; 84 79 83
83. Mitchell A. J., Vancampfort D., Sweers K. et al. Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders - a systematic review and meta-analysis. Schizophr Bull: 2013; 39 306 318
84. Lindenmayer J. P., Khan A., Kaushik S. et al. Relationship between metabolic syndrome and cognition in patients with schizophrenia. Schizophr Res: 2012; 142 171 176
85. Takayanagi Y., Cascella N. G., Sawa A. et al. Diabetes is associated with lower global cognitive function in schizophrenia. Schizophr Res: 2012; 142 183 187
86. McNay E. C., Ong C. T., McCrimmon R. J. et al. Hippocampal memory processes are modulated by insulin and high-fat-induced insulin resistance. Neurobiol Learn Mem: 2010; 93 546 553
87. Yi Z., Fan X., Wang J. et al. Rosiglitazone and cognitive function in clozapine-treated patients with schizophrenia: a pilot study. Psychiatry Res: 2012; 200 79 82
88. Bicikova M., Hampl R., Hill M. et al. Neuro- and immunomodulatory steroids and other biochemical markers in drug-naive schizophrenia patients and the effect of treatment with atypical antipsychotics. Neuro Endocrinol Lett: 2011; 32 141 147
89. Johnson J. Schizophrenia and Cushing's syndrome cured by adrenalectomy. Psychol Med: 1975; 5 165 168
90. Hirsch D., Orr G., Kantarovich V. et al. Cushing's syndrome presenting as a schizophrenia-like psychotic state. Isr J Psychiatry Relat Sci: 2000; 37 46 50
91. Gallagher P., Watson S., Smith M. S. et al. Effects of adjunctive mifepristone (RU-486) administration on neurocognitive function and symptoms in schizophrenia. Biol Psychiatry: 2005; 57 155 161
92. Bubser M., Byun N., Wood M. R. et al. Muscarinic receptor pharmacology and circuitry for the modulation of cognition. Handb Exp Pharmacol: 2012; 208 121 166
93. Tamminga C. Glutamatergic aspects of schizophrenia. Br J Psychiatry: 1999; 37 12 15
94. 1H-MRS studies. Schizophr Bull: 2013; 39 120 129
95. Chaudhry I. B., Husain N., Drake R. et al. Add-on clinical effects of simvastatin and ondansetron in patients with schizophrenia stabilized on antipsychotic treatment: pilot study. Ther Adv Psychopharmacol: 2014; 4 110 116
96. Waters K. A., Stean T. O., Hammond B. et al. Effects of the selective 5-HT(7) receptor antagonist SB-269970 in animal models of psychosis and cognition. Behav Brain Res: 2012; 228 211 218
97. Zimnisky R., Chang G., Gyertyán I. et al. Cariprazine, a dopamine D(3)-receptor-preferring partial agonist, blocks phencyclidine-induced impairments of working memory, attention set-shifting, and recognition memory in the mouse. Psychopharmacology (Berl): 2013; 226 91 100
98. Preskorn S. H., Gawryl M., Dgetluck N. et al. Normalizing effects of EVP-6124, an Alpha-7 nicotinic partial agonist, on event-related potentials and cognition: a proof of concept, randomized trial in patients with schizophrenia. J Psychiatric Pract: 2014; 20 12 24
99. Hashimoto K., Malchow B., Falkai P. et al. Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders. Eur Arch Psychiatry Clin Neurosci: 2013; 263 367 377
100. Tsai G. E., Yang P., Chung L. C. et al. D-serine added to clozapine for the treatment of schizophrenia. Am J Psychiatry: 1999; 156 1822 1825
101. Evins A. E. 1, Fitzgerald S. M., Wine L. et al. Placebo-controlled trial of glycine added to clozapine in schizophrenia. Am J Psychiatry: 2000; 157 826 828
102. Fell M. J., McKinzie D. L., Monn J. A. et al. Group II metabotropic glutamate receptor agonists and positive allosteric modulators as novel treatments for schizophrenia. Neuropharmacology: 2012; 62 1473 1483
103. Fraley M. E. Positive allosteric modulators of the metabotropic glutamate receptor 2 for the treatment of schizophrenia. Expert Opin Ther Pat: 2009; 19 1259 1275
104. Goff D. C., Leahy L., Berman I. et al. A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia. J Clin Psychopharmacol: 2001; 21 484 487
105. Hill S. K., Bishop J. R., Palumbo D. et al. Effect of second-generation antipsychotics on cognition: current issues and future challenges. Expert Rev Neurother: 2010; 10 43 57
106. Desmarais J. E., Beauclair L., Margolese H. C. Anticholinergics in the era of atypical antipsychotics: short-term or long-term treatment? J Psychopharmacol: 2012; 26 1167 1174
107. Woodward N. D. 1, Purdon S. E., Meltzer H. Y. et al. A meta-analysis of cognitive change with haloperidol in clinical trials of atypical antipsychotics: dose effects and comparison to practice effects. Schizophr Res: 2007; 89